WO2005009460A3 - Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer - Google Patents

Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer Download PDF

Info

Publication number
WO2005009460A3
WO2005009460A3 PCT/IB2004/002350 IB2004002350W WO2005009460A3 WO 2005009460 A3 WO2005009460 A3 WO 2005009460A3 IB 2004002350 W IB2004002350 W IB 2004002350W WO 2005009460 A3 WO2005009460 A3 WO 2005009460A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
activin
alk
derivatives
treatment
Prior art date
Application number
PCT/IB2004/002350
Other languages
French (fr)
Other versions
WO2005009460A2 (en
Inventor
Theodore Fotsis
Original Assignee
Medexis S A
Theodore Fotsis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20030100319A external-priority patent/GR1004610B/en
Priority claimed from GR20030100362A external-priority patent/GR1004865B/en
Application filed by Medexis S A, Theodore Fotsis filed Critical Medexis S A
Publication of WO2005009460A2 publication Critical patent/WO2005009460A2/en
Publication of WO2005009460A3 publication Critical patent/WO2005009460A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprising activin A, ALK-4 or derivatives thereof is described. Such compositions may be used in the treatment of ophthal­mic disorders or cancer with the proviso that if the cancer is skin cancer the compound is not activin A.
PCT/IB2004/002350 2003-07-25 2004-07-22 Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer WO2005009460A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GR20030100319A GR1004610B (en) 2003-07-25 2003-07-25 Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of cancer
GR20030100319 2003-07-25
US49397503P 2003-08-08 2003-08-08
US60/493,975 2003-08-08
GR20030100362A GR1004865B (en) 2003-09-02 2003-09-02 PHARMACEUTICAL COMPOSITION COMPRISING ACTIVIN a, aLK-4 OR DERIVATIVES THEREOF FOR THE TREATMENT OF OPHTHALMIC DISEASES
GR20030100362 2003-09-02
US50204703P 2003-09-10 2003-09-10
US60/502,047 2003-09-10

Publications (2)

Publication Number Publication Date
WO2005009460A2 WO2005009460A2 (en) 2005-02-03
WO2005009460A3 true WO2005009460A3 (en) 2005-12-01

Family

ID=34108965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002350 WO2005009460A2 (en) 2003-07-25 2004-07-22 Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer

Country Status (1)

Country Link
WO (1) WO2005009460A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (en) 2004-07-23 2013-10-18 Acceleron Pharma Inc. ACTRII receptor polypeptides, procedures and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN105001320A (en) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
WO2008060139A1 (en) * 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
MX2009006651A (en) * 2006-12-18 2009-08-26 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels.
AU2016250354B2 (en) * 2006-12-18 2019-01-17 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (en) 2007-02-01 2016-10-26 阿塞勒隆制药公司 Activin-ACTRIIA antagonist and the purposes in treatment or Breast Cancer Prevention
TW202021980A (en) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
ME02333B (en) 2007-02-09 2013-04-30 Acceleron Pharma Inc PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVIN-ActRIIA ANTAGONISTS AND USE THEREOF IN PREVENTING OR TREATING MULTIPLE MYELOMA
CN101861161B (en) 2007-09-18 2017-04-19 阿塞勒隆制药公司 Activin-ACTRIIA antagonists and uses for decreasing or inhibiting FSH secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI748373B (en) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 Use of gdf traps to increase red blood cell levels
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc Methods for increasing adiponectin
MX2011013172A (en) 2009-06-08 2012-04-02 Acceleron Pharma Inc Methods for increasing thermogenic adipocytes.
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (en) 2010-11-08 2013-09-11 阿塞勒隆制药公司 ACTRIIA binding agents and uses thereof
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
EP4233889A3 (en) 2014-12-03 2023-10-11 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CN111850043A (en) * 2020-06-28 2020-10-30 武汉纽福斯生物科技有限公司 ECEL1 recombinant adeno-associated virus vector and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) * 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) * 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FLORIDA, USA; MAY 05-10, 2002, pages Abstract No. 1862 *
BILEZIKJIAN LOUISE M ET AL: "Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells", ENDOCRINOLOGY, vol. 142, no. 3, March 2001 (2001-03-01), pages 1065 - 1072, XP002337139, ISSN: 0013-7227 *
BONDESTAM JONAS ET AL: "Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 195, no. 1-2, 30 September 2002 (2002-09-30), pages 79 - 88, XP008050180, ISSN: 0303-7207 *
DALKIN A C ET AL: "ACTIVIN INHIBITION OF PROSTATE CANCER CELL GROWTH: SELECTIVE ACTIONS ON ANDROGEN-RESPONSIVE LNCAP CELLS", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 137, no. 12, December 1996 (1996-12-01), pages 5230 - 5235, XP000987189, ISSN: 0013-7227 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, RADETZKY S ET AL: "Activin A Stimulates Inflammatory Corneal Neovascularization.", XP002971894, Database accession no. PREV200300143583 *
ENGELSE MARTEN A ET AL: "Adenoviral activin A expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype", CIRCULATION RESEARCH, vol. 90, no. 10, 31 May 2002 (2002-05-31), pages 1128 - 1134, XP002319922, ISSN: 0009-7330 *
MCPHERSON S J ET AL: "GROWTH INHIBITORY RESPONSE TO ACTIVIN A AND B BY HUMAN PROSTATE TUMOUR CELL LINES LNCAP AND DU145", JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 154, 1997, pages 535 - 545, XP002929639, ISSN: 0022-0795 *
YAMAMOTO T ET AL: "Expression and possible roles of activin A in proliferative vitreoretinal diseases.", JAPANESE JOURNAL OF OPHTHALMOLOGY. 2000 MAY-JUN, vol. 44, no. 3, May 2000 (2000-05-01), pages 221 - 226, XP002288775, ISSN: 0021-5155 *

Also Published As

Publication number Publication date
WO2005009460A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2003080582A3 (en) Fredericamycin derivatives
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004105773A3 (en) Use of s1p
WO2007133944A3 (en) Topical administration of acyclovir
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2007109093A3 (en) Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase